Showing results (101-110 of 130) with videos related to
Sort By:
Pageof 13
American Journal of Respiratory and Critical Care Medicine|May 8, 2010
Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosisJerry A Nick, Cathy S Chacon, Sara J Brayshaw, et al.Annals of the American Thoracic Society|March 16, 2026
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: Results from an open-label extension studyJames F Chmiel, Kimberly McBennett, Bradley S Quon, et al.The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 14, 2024
Prioritizing sexual and reproductive health research and care for people with cystic fibrosis: A 2023 workshop report from the Cystic Fibrosis Foundation Sexual Health, Reproduction, and Gender (SHARING) Research Working GroupTraci M Kazmerski, Christie Moy, Enid Aliaj, et al.The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.American Journal of Respiratory and Critical Care Medicine|April 10, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension StudyCori L Daines, Deepika Polineni, Elizabeth Tullis, et al.The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.Pageof 13